Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 19/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20454505 | 0.90 | RORC (0.48) | RORCCNR2 | |
| SCHEMBL20454537 | 0.85 | RORC (0.47) | RORCCNR2 | |
| SCHEMBL19183244 | 0.82 | KIF11 (0.40) | RORC | |
| SCHEMBL20454748 | 0.79 | RORC (0.39) | RORC | |
| SCHEMBL20454538 | 0.76 | RORC (0.41) | RORC | |
| SCHEMBL20454715 | 0.75 | RORC (0.48) | RORC | |
| SCHEMBL20454717 | 0.74 | RORC (0.48) | RORC | |
| SCHEMBL18440520 | 0.72 | ROCK2 (0.36) | — | |
| SCHEMBL20454631 | 0.72 | RORC (0.53) | RORCCNR2 | |
| SCHEMBL20454349 | 0.71 | RORC (0.41) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | disclosed |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | RORB, RORC, RORA | RORC 2/4885CNR2 151/4885 |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RORC 2/4885CNR2 750/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RORC 2/4885CNR2 750/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | RORC 1/4885CNR2 441/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | RORC 1/4885CNR2 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.